The EU-funded project AIDPATH, a collaboration between twelve partners from seven countries, is aiming to increase patient’s access to CAR-T cell therapy, a promising treatment for blood cancers such ...

On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, ...

National Footprint of NEXICART-2 Trial Sites Expanded - - On track for first Biologics License Application (BLA) approved ...

Coverage from “Tech Innovations in Oncology,” presented June 19, 2025, by Tennessee Oncology in Nashville, Tennessee. First ...

Experimental treatment could offer a safer, cheaper alternative to CAR T cell therapies for disorders such as lupus.